A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.

赞助:

合作者:

信息的提供 (责任方):

，

追踪信息

首次提交日期 ^ICMJE

September 21, 2018

首次发布日期e ^ICMJE

October 2, 2018

最后更新发布日期

October 2, 2018

预计研究开始日期 ^ICMJE

May 30, 2018

预计主要完成日期

October 2018 (主要结果测量的最终数据收集日期)

目前主要观察指标 ^ICMJE

24 hour total urinary NNAL (mg/24 hours) excreted on Day 7.[ Time Frame: Day 7 ]

24 hour total urinary NNAL

原始主要观察测量 ^ICMJE

与当前相同

目前的二级观察 ^ICMJE

24 hour urinary total total NNN, NE, 2-AN, 4-ABP, HEMA, CEMA, S-PMA, 3 HMPMA, 3-HPMA, 2-HPMA, AAMA, GAMA, 2-MHBMA, 2 OHFle, 2-Naphthol, 1 OHPhe, mutagenicity, and 1-OHP excreted on Day 5 and Day 7.[ Time Frame: Day 5 and 7 ]
24 hour urinary total total NNN, NE, 2-AN, 4-ABP, HEMA, CEMA, S-PMA, 3 HMPMA, 3-HPMA, 2-HPMA, AAMA, GAMA, 2-MHBMA, 2 OHFle, 2-Naphthol, 1 OHPhe, mutagenicity, and 1-OHP
24-hour urinary total NNAL excreted on Day 5.[ Time Frame: Day 5 ]
24-hour urinary total NNAL
COHb on Day 5 and Day 7.[ Time Frame: Day 5 and 7 ]
COHb
Questionnaire of Smoking Urges-Brief[ Time Frame: Day 1, 5 and 7 ]
The QSU-Brief is a 10-item instrument (Cox et al., 2001) intended to capture urge to smoke. Participants respond to the 10 items using a 7-point Likert-type rating scale ranging from Strongly Disagree to Strongly Agree. Both a total score (reflecting urge to smoke) and two factor scores (Factor 1: Intention to smoke with smoking perceived as rewarding; Factor 2: anticipation of relief from negative affect with an urgent desire to smoke) will be calculated by averaging the items.
Modified Cigarette Evaluation Questionnaire[ Time Frame: Day 1, 5 and 7 ]
The modified cigarette evaluation questionnaire (mCEQ) is a 12-item instrument intended to capture the degree to which a person experiences the reinforcing effects of smoking from 1 (Not at All) to 7 (Extremely) (Cappelleri et al., 2007). Scores for the five mCEQ subscales range from 1 to 7, with higher scores reflecting greater smoking satisfaction, psychological reward, aversion, enjoyment of respiratory tract sensations, and craving reduction.
Use the Product Again Questionnaire[ Time Frame: Day 7 ]
The "Use this Product Again Questionnaire" is a single-item bipolar visual analogue scale (VAS). Subjects are asked to respond to this item using a 100 mm VAS with three labeled points: "Definitely Would Not," "Don't Care" and "Definitely Would".
Product use behavior[ Time Frame: Day 1 to Day 7 ]
The number of each product used per day (cigarettes and OTDN products) and the duration of each OTDN product used during each product use period will be listed and summarized by study product.

描述性信息

简略标题 ^ICMJE

A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.

正式标题 ^ICMJE

A Randomized, Controlled, Study to Evaluate Changes in Exposure to Harmful and Potentially Harmful Constituents in Adult Smokers Who Partially or Completely Switch to Oral Tobacco-derived Nicotine Products in a Clinical Setting.

简要概况

The purpose of this study is to evaluate changes in exposure to selected harmful and potentially harmful constituents (HPHC) by measuring biomarkers in adult smokers who partially or completely switch from smoking cigarettes to oral tobacco-derived nicotine (OTDN) products compared to those who continue exclusive smoking cigarettes or stop using all tobacco products.

详细说明

This is an open label, randomized, 6 parallel-group clinical study evaluating changes in exposure to selected HPHCs, subjective effects, and product use behavior in adult smokers relative to continued smoking who are randomly assigned to continue smoking, partially or completely switch to oral tobacco-derived nicotine products, or stop using any tobacco products for 7 days.

研究类型 ^ICMJE

Interventional

研究阶段

N/A

研究设计 ^ICMJE

分配: Randomized
干预模型: Parallel Assignment
干预模型描述:
盲法: Interventional
盲法描述:
主要目的: Other

适用条件 ^ICMJE

干预项目 ^ICMJE

Other: OTDN product 1
Oral tobacco-derived nicotine product
Other: OTDN product 2
Oral tobacco-derived nicotine product
Other: Tobacco Cessation
Tobacco Cessation

研究工具

No Intervention: GROUP 1: Continue Smoking
Subjects will be asked to continue smoking their OB cigarettes ad libitum for 7 days.
Experimental: GROUP 2: OTDN product 1
Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
Experimental: GROUP 3: OTDN product 2
Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
Experimental: GROUP 4: OTDN product 1
Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
Experimental: GROUP 5: OTDN product 2
Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
Experimental: GROUP 6: Tobacco Cessation
Subjects will completely stop all tobacco product usage for 7 days.

招募信息

招募状态 ^ICMJE

Recruiting

预计入组 ^ICMJE

210

原始预计入组 ^ICMJE

与当前相同

预计研究完成日期

October 2018

预计主要完成日期

October 2018 (主要结果测量的最终数据收集日期)

合格标准 ^ICMJE

Inclusion Criteria: 1. Voluntary consent to participate in this study documented on the signed informed consent form (ICF). 2. Healthy adult males and females 21 to 65 years of age, inclusive, at Screening 3. Smoking history of an average of at least 10 but no more than 30 factory manufactured combustible cigarettes daily for at least 1 year prior to Screening. Brief periods (i.e., up to 7 consecutive days) of non-smoking during the 3 months prior to Screening (e.g., due to illness or participation in a study where smoking was prohibited) will be permitted. 4. Positive urine cotinine (≥ 500 ng/mL) at Screening. 5. Willing to comply with the requirements of the study. 6. Willing to use all test products after product trial at Check in. 7. Willing and able to abstain from cigarettes from Day 1 through the End of the study. Exclusion Criteria: 1. Use of any type of tobacco or nicotine containing products other than manufactured cigarettes (e.g., e vapor products, roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) in the 7 days prior to Check in 2. Self-reported puffers (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale). 3. Planning to quit smoking in the next 30 days (from Screening visit). 4. History or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, existing respiratory diseases, immunologic, psychiatric, lymphatic, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results. 5. Clinically significant abnormal findings on the vital signs, physical examination, medical history, ECG, or clinical laboratory results, in the opinion of the Investigator.

性别

参与研究的性别:

All

年龄

最小年龄：21 Years ，最大年龄：65 Years

接受健康的志愿者

没有

可入组国家 ^ICMJE

United States

管理信息

数据检测委员会

研究涉及美国FDA监管的产品

研究美国FDA监管的药品: No
研究涉及美国FDA监管的设备产品: No

IPD 共享声明

计划分享 IPD:

责任方

，

研究赞助商 ^ICMJE

Altria Client Services LLC

合作者 ^ICMJE

研究员 ^ICMJE

Study Director: Georgios D Karles, PhD Altria Client Services LLC

PRS 账户

验证日期

September 2018

^ICMJE 国际医学期刊编辑委员会和世界卫生组织 ICTRP 要求的元素

请使用微信扫码报名